ZIVO vs. CTNM, DBVT, GALT, VOR, JBIO, LXEO, PBYI, ALLO, IMMP, and EDIT
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Contineum Therapeutics (CTNM), DBV Technologies (DBVT), Galectin Therapeutics (GALT), Vor Biopharma (VOR), Jade Biosciences (JBIO), Lexeo Therapeutics (LXEO), Puma Biotechnology (PBYI), Allogene Therapeutics (ALLO), Prima BioMed (IMMP), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry.
ZIVO Bioscience vs. Its Competitors
Contineum Therapeutics (NASDAQ:CTNM) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.
ZIVO Bioscience has lower revenue, but higher earnings than Contineum Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Contineum Therapeutics had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Contineum Therapeutics and 1 mentions for ZIVO Bioscience. Contineum Therapeutics' average media sentiment score of 0.70 beat ZIVO Bioscience's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media.
ZIVO Bioscience's return on equity of 0.00% beat Contineum Therapeutics' return on equity.
12.8% of ZIVO Bioscience shares are owned by institutional investors. 11.3% of Contineum Therapeutics shares are owned by insiders. Comparatively, 21.5% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Contineum Therapeutics presently has a consensus price target of $22.75, indicating a potential upside of 107.01%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Contineum Therapeutics is more favorable than ZIVO Bioscience.
Contineum Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500.
Summary
Contineum Therapeutics beats ZIVO Bioscience on 10 of the 16 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:ZIVO) was last updated on 9/5/2025 by MarketBeat.com Staff
Free ZIVO Stock Alerts